Asya Grinberg

USPTO Granted Patents = 65 (Patent Applications = 68)

CIPO Patents = 7 (Patent Applications = 46)

EPO Patents = 20 (Patent Applications = 71)

Average Co-Inventor Count = 4.5

ph-index = 7

Forward Citations = 142(Granted Patents)

Forward Citations (Not Self Cited) = 58(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Boston, MA (US) (2010 - 2014)
Lexington, MA (US) (2014 - 2024)
Cambridge, MA (US) (2019 - 2024)

Company Filing History:

50 out of 167

Acceleron Pharma Inc.

patents

12 out of 14

Dragonfly Therapeutics, Inc.

The Brigham and Women's Hospital, Inc.

Ludwig Institute for Cancer Research Limited

patents

8. 1 out of 1

Accerelon Pharma Inc.

patent

9. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

TGF-Beta Receptors

Multi-Specific Binding Proteins

NKG2D Antibodies

ALK7 Antagonists

Muscular Dystrophy Treatments

Cancer Immunotherapy

Heteromultimeric Proteins

Endoglin Peptides

Follistatin Polypeptides

Tumor-Associated Antigens

Pulmonary Hypertension Therapies

Variant ActRIIB Proteins

65 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421295 - TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof (2025-09-23),

2. 12384851 - Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use (2025-08-12),

3. 12384847 - Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen (2025-08-12),

4. 12378318 - Proteins binding NKG2D, CD16 and a tumor-associated antigen (2025-08-05),

5. 12365736 - ALK7 binding proteins and uses thereof (2025-07-22),

6. 12338273 - Single-arm type I and type II receptor fusion proteins and uses thereof (2025-06-24),

7. 12275791 - Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use (2025-04-14),

8. 12264200 - Antibody variable domains targeting the NKG2D receptor (2025-04-01),

9. 12258380 - ALK4:actriib heteromultimers and uses thereof (2025-03-25),

10. 12240887 - Variant ActRIIB proteins and uses thereof (2025-03-04),

11. 12215157 - Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use (2025-02-04),

12. 12157771 - Proteins binding NKG2D, CD16 and CLEC12A (2024-12-03),

13. 12145970 - Twisted gastrulation polypeptides and uses thereof (2024-11-19),

14. 12144860 - ALK1 receptor and ligand antagonists and uses thereof (2024-11-19),

15. 12129300 - Antibody variable domains targeting the NKG2D receptor (2024-10-29),

Title: The Innovative Journey of Asya Grinberg

Introduction: Asya Grinberg, a pioneering inventor based in Lexington, MA, has made significant contributions to the field of technology with her groundbreaking innovations.

Latest Patents: Asya Grinberg holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing her diverse range of expertise and creativity.

Career Highlights: With a background in engineering and a passion for problem-solving, Asya Grinberg has led successful projects that have revolutionized industries and improved the lives of many.

Collaborations: Throughout her career, Asya Grinberg has collaborated with top research institutions, leading companies, and talented individuals to bring her ideas to life and create impactful solutions.

Conclusion: Asya Grinberg's dedication to innovation and her relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

This text is generated by artificial intelligence and may not be accurate.